Earnings calls

Laurus Labs concall ledger

Every earnings call for LAURUSLABS — management tone, guidance, KPIs and promise tracking, quarter by quarter.

LAURUSLABS · 5 transcripts · Healthcare · latest Q4 FY26

Q4 FY26Published 30 Apr 2026Call held 30 Apr 2026

LAURUSLABS Q4 FY26 Earnings Call Transcript & Analysis

Revenue₹6,813 cr+23% YoYEBITDA₹1,826 crEBITDA Margin26.8%+7% YoYPAT₹889 cr+148% YoYGross Margin61.4%

Revenue (FY26) ₹6,813 cr (+23% YoY); EBITDA (FY26) ₹1,826 cr; EBITDA Margin (FY26) 26.8% (+7% YoY). Revenue of ₹6,813 crores, up 23% YoY for FY26.

Q2 FY26Published 23 Jan 2026Call held 23 Jan 2026

EBITDA₹485 crEBITDA Margin27%Profit After Tax₹252 crGross Margin60.9%Net Debt₹2,092 cr

EBITDA (Q3) ₹485 cr; EBITDA Margin (Q3) 27%; Profit After Tax (Q3) ₹252 cr. Q3 Revenue of ₹1,778 crores, up 26% YoY.

Q1 FY26Published 23 Oct 2025Call held 23 Oct 2025

EBITDA₹429 crEBITDA Margin26%PAT₹195 crGross Margin59.9%ROCE16.3%

EBITDA (Q2) ₹429 cr; EBITDA Margin (Q2) 26%; PAT (Q2) ₹195 cr. Revenue of ₹1,653 crores, up 35% YoY.

Q4 FY25Published 25 Jul 2025Call held 25 Jul 2025

Revenue₹1,570 cr+31% YoYEBITDA₹389 crEBITDA Margin25%PAT₹163 crGross Margin59.5%

Revenue ₹1,570 cr (+31% YoY); EBITDA ₹389 cr; EBITDA Margin 25%. Revenue of ₹1,570 crores, up 31% YoY.

Q3 FY25Published 24 Apr 2025Call held 24 Apr 2025

EBITDA₹477 crEBITDA Margin27.7%PAT₹234 crGross Margin54.5%ROCE9.7%

EBITDA (Q4) ₹477 cr; EBITDA Margin (Q4) 27.7%; PAT (Q4) ₹234 cr. Q4 FY25 Revenue of ₹1,720 crores, up 19% YoY.